Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years

/在：

 

Created
Tags CGMHOPH Pediatric Refraction
Journal JAMA Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

JAMA Ophthalmology Published online June 1, 2023

中文摘要

這項研究旨在評估低劑量阿托品眼藥水在減緩兒童近視（近視）進展方面的療效和安全性。

以下是摘錄中提到的主要研究結果：

  • 該研究納入了576名參與者，並將其隨機分配到治療組。
  • 主要療效結果是在36個月時近視進展小於0.50屈光度的參與者比例。
  • 低劑量阿托品，具體濃度為0.01%和0.02%，與安慰劑進行比較。
  • 在36個月時，與安慰劑相比，低劑量阿托品0.01%顯著增加了反應者（近視進展較少的參與者）的比例，並減緩了球面等效屈光（SER）進展和軸向伸長（眼睛的加長）。
  • 低劑量阿托品0.02%在減緩軸向伸長方面具有益處，但並未顯著增加反應者比例或減緩SER進展。
  • 安全評估顯示，這兩種低劑量阿托品濃度都是安全且耐受良好的。
  • 研究結論是，特別是0.01%濃度的低劑量阿托品可能為兒童近視進展提供一種治療選擇。

重要的是要注意，這只是完整研究文章的一小部分，研究結果應該在完整研究的背景下進行解讀。為了獲得更詳細的信息和全面了解研究，建議閱讀完整的文章。

English Abstract

Place English abstract here

The study aimed to evaluate the efficacy and safety of low-dose atropine eye drops in slowing the progression of myopia (nearsightedness) in children.

Here are the key findings mentioned in the excerpt:

  • The study included 576 participants who were randomly assigned to treatment groups.
  • The primary efficacy outcome was the proportion of participants with less than 0.50 diopters of myopia progression at month 36.
  • Low-dose atropine, specifically at concentrations of 0.01% and 0.02%, was compared with a placebo.
  • At month 36, compared to the placebo, low-dose atropine 0.01% significantly increased the proportion of responders (participants with less myopia progression) and slowed mean spherical equivalent refractive (SER) progression and axial elongation (lengthening of the eye).
  • Low-dose atropine 0.02% showed benefit in slowing axial elongation but did not significantly increase the proportion of responders or slow SER progression.
  • Safety assessments indicated that both low-dose atropine concentrations were safe and well-tolerated.
  • The authors concluded that low-dose atropine, particularly at a concentration of 0.01%, may provide a treatment option for childhood myopia progression.

It’s important to note that this is only a small portion of the full research article, and the findings should be interpreted in the context of the complete study. For more detailed information and a comprehensive understanding of the research, it is recommended to read the full article.

Systemic Adverse Events Among Patients With Diabetes Treated With Intravitreal Anti–Vascular Endothelial Growth Factor Injections

/在：

 

Created
Tags Retina
Journal JAMA Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

JAMA Ophthalmology Published online June 1, 2023

中文摘要

此研究探討了糖尿病患者使用玻璃體內抗血管內皮生長因子（anti-VEGF）藥物的全身安全性。作者旨在評估糖尿病患者使用玻璃體內anti-VEGF治療與全身不良事件風險之間的關聯。

該研究納入了1731782名2型糖尿病患者的大型群體。從2013年1月1日至2017年12月31日期間提取了該患者群體中不良全身事件的數據。研究人員在控制年齡、性別、種族、族裔、吸煙習慣、糖尿病視網膜病變（DR）嚴重程度、合併症負擔和其他變量等各種因素的基礎上，評估了玻璃體內anti-VEGF注射與全身不良事件發展之間的關聯。

研究結果顯示，玻璃體內anti-VEGF治療獨立與全身不良事件的風險增加有關，包括急性心肌梗塞、心血管疾病和腎臟疾病。與全身不良事件風險增加相關的其他因素包括年齡較大、男性、吸煙、非白人種族、較高的DR嚴重程度和合併症負擔。

該研究強調了在考慮糖尿病患者使用玻璃體內anti-VEGF藥物時要考慮其全身安全性。雖然先前的研究報告結果不一，但這項大型群體研究提供了來自臨床實踐的寶貴數據。研究結果表明，在臨床決策中，醫生在考慮給糖尿病患者使用anti-VEGF治療時應謹慎，特別是對於那些更容易出現全身不良事件的患者。

值得注意的是，該研究存在一定的限制，包括依賴診斷的計費代碼、編碼可能存在的不準確性以及未對糖尿病持續時間進行控制。需要進一步進行樣本量更大、追蹤時間更長的研究來確認和更好地理解這些結果。

總的來說，該研究對於糖尿病患者使用玻璃體內anti-VEGF治療的全身安全性的現有文獻作出了貢獻，並強調在臨床決策中需要仔細考慮潛在的風險和益處。

English Abstract

The study explores the systemic safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents among patients with diabetes. The authors aimed to assess the risk of systemic adverse events associated with intravitreal anti-VEGF therapy in patients with diabetes.

The study included a large cohort of 1,731,782 patients with type 2 diabetes. Data on incident systemic adverse events among this patient cohort were extracted from January 1, 2013, to December 31, 2017. The researchers evaluated the association between intravitreal anti-VEGF injections and the development of systemic adverse events while controlling for various factors such as age, sex, race, ethnicity, tobacco use, severity of diabetic retinopathy (DR), comorbidity burden, and other variables.

The results of the study indicated that intravitreal anti-VEGF therapy was independently associated with a higher likelihood of systemic adverse events, including acute myocardial infarction, cardiovascular disease, and kidney disease. Other factors that were associated with an increased risk of systemic adverse events included older age, male sex, tobacco use, non-White race, higher DR severity, and comorbidity burden.

The study highlights the importance of considering the systemic safety profile of intravitreal anti-VEGF agents in patients with diabetes. While previous studies have reported mixed results, this large cohort study provides valuable data from a clinical practice setting. The findings suggest that clinicians should be cautious when considering anti-VEGF therapy in patients with diabetes, especially those at higher risk for systemic adverse events.

It is important to note that this study has certain limitations, including its reliance on billing codes for diagnoses, potential inaccuracies in coding, and the lack of control for the duration of diabetes. Further research with larger sample sizes and longer follow-up periods is needed to confirm and better understand these findings.

Overall, this study contributes to the existing body of literature on the systemic safety of intravitreal anti-VEGF therapy in patients with diabetes and emphasizes the need for careful consideration of potential risks and benefits in clinical decision-making.

Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity

/在：

 

Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity

Created
Tags Retina
Journal Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

Ophthalmology 2023;130:373-378 ª 2022 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmolog

中文摘要

此研究比較了治療早產兒視網膜病變的兩種靜脈內注射藥物，Bevacizumab和Ranibizumab，並探討不同劑量或類型的抗血管內皮生長因子(VEGF)是否與再次治療有關。研究收集了661名患者873只眼睛的數據。主要分析的樣本包括307名患者的567只眼睛，其中沒有再次治療和再次治療兩組在出生體重、胎齡、首次注射年齡、ROP階段或受影響的時鐘小時數等方面沒有差異。然而，再次治療組中，有較大比例的ROP較為aggressive(34%對18%)，並且有更大比例的第一區ROP(49對34%)。研究結果發現，Ranibizumab的使用與較高的再次治療率相關，而Bevacizumab的較低劑量與再次治療相關。

English Abstract

This study compares the retreatments between Bevacizumab and Ranibizumab intravitreal injections in treating Retinopathy of Prematurity (ROP), examining if specific dosages or types of anti-vascular endothelial growth factors (VEGF) are associated with retreatment. Data from 873 eyes of 661 patients were collected. The primary analysis included 567 eyes of 307 patients, where no significant difference was found between the no retreatment and retreatment groups in terms of birthweight, gestational age, age at first injection, ROP stages, or number of involved clock hours. However, the retreatment group had a larger percentage of aggressive ROP (34% vs 18%) and a greater percentage of zone 1 ROP (49% vs 34%). The results found that lower doses of Bevacizumab were associated with higher retreatment rates than higher doses of Bevacizumab; the use of Ranibizumab was associated with a higher rate of retreatment, , whereas the rate of retreatment was not associated with a specific dose of ranibizumab. In a multicenter study of ROP patients initially treated with anti-VEGF therapy, ranibizumab and lower-dose bevacizumab use were associated with an increased rate of retreatment when compared with higher dose bevacizumab.

Reticular Pseudodrusen Status, ARMS2/HTRA1 Genotype, and Geographic Atrophy Enlargement

/在：

 

Reticular Pseudodrusen Status, ARMS2/HTRA1 Genotype, and Geographic Atrophy Enlargement

Created
Tags Retina
Journal Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

Ophthalmology Volume 130, Number 5, May 2023

中文摘要

本研究旨在探討網狀偽黃斑病變(reticular pseudodrusen, RPD)狀態、ARMS2/HTRA1基因型或兩者是否與地理性黃斑退化(geographic atrophy, GA)擴大速率有關，並分析RPD狀態對基因效應的可能調節作用。結果顯示，RPD狀態並未調節ARMS2/HTRA1基因型與更快擴大之間的關聯。RPD的存在和ARMS2/HTRA1基因型相對獨立的風險因素，運作的機制也不同。對GA擴大速率的準確預測對臨床試驗的有效性和精準度至關重要。就此問題進行研究可以明確是否需要進行基因測試以達到最佳的準確性，或者僅需用影像特徵（包括RPD狀態）即可。研究還發現GA的擴大在有RPD的眼睛中明顯更快。然而，儘管ARMS2風險等位基因與RPD的存在有關，而RPD的存在又與GA的快速擴大有關，但透過RPD狀態的這種間接關係似乎並未產生任何顯著的影響。

English Abstract

This study aimed to determine whether the status of reticular pseudodrusen (RPD), the ARMS2/HTRA1 genotype, or both are associated with the enlargement rate of geographic atrophy (GA) and to analyze any potential mediation of genetic effects by RPD status. The findings showed that RPD status does not mediate the association between the ARMS2/HTRA1 genotype and faster enlargement. The presence of reticular pseudodrusen and the ARMS2/HTRA1 genotype are relatively independent risk factors, operating by distinct mechanisms. Accurate predictions of the GA enlargement rate are crucial for the power and precision of clinical trials. Addressing these questions should clarify whether genetic testing would be required for optimal accuracy or whether imaging features (including RPD status) would suffice. The study also found that GA enlargement is significantly faster in eyes with RPD. However, despite the fact that ARMS2 risk alleles are associated with RPD presence, which in turn is associated with faster GA enlargement, this potential indirect relationship via RPD status does not seem to make any meaningful contribution.

Comparison of Snellen Visual Acuity Measurements in Retinal Clinical Practice to Electronic ETDRS Protocol Visual Acuity Assessment

/在：

 

Comparison of Snellen Visual Acuity Measurements in Retinal Clinical Practice to Electronic ETDRS Protocol Visual Acuity Assessment

Created
Tags Retina
Journal Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

Ophthalmology Volume 130, Number 5, May 2023

中文摘要

這項研究關注了臨床和protocol視力測量之間的潛在差異，研究對象是參與了DRCR Protocols AC、AE 和 W 的參與者。這些研究對象的眼睛在臨床和protocol訪問之間沒有接受過治療。研究發現，即使進行了屈光度矯正，臨床視力測量仍然比 eETDRS protocol視力測量低約1行。此外，臨床視力測量與protocol視力測量之間的時間差距並未顯現出明顯的關聯。平均而言，臨床 Snellen 視力測量值比 eETDRS protocol屈光度檢查和視力測試差了1至2行，這可能部分解釋了為什麼臨床上並不總是能夠複製臨床試驗的結果。那些臨床測量值較低的眼睛和未進行臨床屈光度檢查的眼睛通常會有更大的差異。因此，研究建議在確定治療計劃和臨床試驗轉介時應對患者進行屈光度矯正。

English Abstract:

This study focuses on potential discrepancies between clinical and protocol visual acuity (VA) measurements, examining participants in DRCR Protocols AC, AE, (diabetic macular edema), and W (nonproliferative diabetic retinopathy). These participants’ eyes received no treatment between the clinical and protocol visits. The study found that even with refraction, clinical VA still measured approximately 1 line worse than the eETDRS protocol VA. Furthermore, there was no apparent association between the VA differences and the time gap between clinical and protocol measurements. On average, clinical Snellen VA is 1 to 2 lines worse than eETDRS protocol refraction and VA testing, which may partly explain why clinical practice does not always replicate clinical trial results. Eyes with lower clinical measurements and eyes tested without clinical refraction tended to have larger differences. Considering the potential discrepancies between clinical and protocol VA measurements, refracting eyes in the
clinic may benefit patients when determining treatment plans and study referrals based on vision.

Navigating Coronavirus Disease 2019 Vaccination and Uveitis: Identifying the Rates and Risk of Recurrent Uveitis after Coronavirus Disease Vaccination

/在：

 

Navigating Coronavirus Disease 2019 Vaccination and Uveitis: Identifying the Rates and Risk of Recurrent Uveitis after Coronavirus Disease Vaccination

Created
Tags CGMHOPHUveitis
Journal Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

中文摘要

這篇文章主要研究冠狀病毒疫苗接種後葡萄膜炎復發的比率和風險。來自奧克蘭區的炎性眼病登記病患被納入研究，研究者查詢他們的疫苗接種日期並進行了分析。結果發現，曾有復發病史、慢性葡萄膜炎患者以及病情穩定期較短的患者在接種疫苗後的復發風險最高。在接種疫苗後21至30天內，新出現的葡萄膜炎或復發的葡萄膜炎案例也有所增加，但由於大多數報告都是個案或小型病例系列，尚不清楚是否存在真實的相關性。在接種第一劑和第二劑疫苗後的兩個月以及接種第三劑疫苗後的六週，葡萄膜炎復發風險最高。研究結果證實，已知有葡萄膜炎病史的患者，接種疫苗後的復發風險比基線高出129%。最後，研究確認，無論是感染性還是非感染性葡萄膜炎，疫苗接種都與葡萄膜炎復發的風險增加有關。

English Abstract

This article investigates the rates and risks of recurrent uveitis following the COVID-19 vaccination. Subjects were drawn from the Inflammatory Eye Disease Registry in the Auckland District, and their vaccination dates were accessed and analyzed. The risk was found to be highest among those with previous recurrences, chronic uveitis, and a shorter period of quiescence. An increase in de novo uveitis or recurrence of uveitis within 21 to 30 days post-vaccination was observed, though due to the preponderance of individual cases or small case series, a definitive association is yet to be ascertained. The hazard of uveitis flare was highest at two months post-vaccination for the first and second doses and at six weeks after the third dose. The current study demonstrates an increased risk of uveitis flare after the first dose of COVID
vaccination. This risk was highest in those with previous recurrences, chronic uveitis, and shorter period of quiescence.

Reports：Association between Aphakia and Endophthalmitis after Pediatric Cataract Surgery

/在：

 

Reports：Association between Aphakia and Endophthalmitis after Pediatric Cataract Surgery

Created
Tags CGMHOPHPediatricRetina
Journal Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

Ophthalmology Volume 130, Number 5, May 2023

中文摘要

本研究探討了小兒白內障手術後眼內炎的相關因素，特別是無晶狀體狀態（Aphakia）。眼內炎是白內障手術後罕見但毀滅性的併發症，其在兒童中的發生率遠高於成人。此項研究使用了大型索賠數據庫，並發現，患有眼內炎的病患更有可能有無晶狀體或創傷的病史。在年齡小於1歲且無晶狀體的患者中，眼內炎的概率更高。無晶狀體與網膜脫落、玻璃體出血、傷口修復和secondary IOL implantation等有顯著關聯，其中，玻璃體出血和網膜脫落與眼內炎有關。總的來說，無晶狀體可被視為年長兒童內眼炎的獨立預測因素。

另一研究描述了由凝膠彈射物引起的眼傷的案例。凝膠彈射物可以導致嚴重的視覺損傷，可能需要進行手術治療，尤其是在前房出血情況下無法控制眼壓的情況。雖然大部分患者在最後恢復到20/20或20/25的視力，但他們可能仍面臨終身的眼部併發症如青光眼的風險。

English Abstract

This study aimed to identify factors associated with endophthalmitis, a severe but rare complication of pediatric cataract surgery. Utilizing a large claims database, the IBM MarketScan Research Database, it was found that children have a significantly higher incidence of endophthalmitis compared to adults. The study also revealed a strong association between aphakia (absence of the lens in the eye) and endophthalmitis in children aged 1 year or younger. Other associated factors include a history of trauma, retinal detachment, vitreous hemorrhage, wound revision, and secondary intraocular lenses. However, the study doesn’t imply that intraocular lenses are protective against endophthalmitis.

In a separate retrospective case series, the study looked at ocular injuries resulting from gel pellet projectiles fired from gel blaster guns. It was found that these injuries can result in severe visual impairment and may require surgical intervention, especially in the case of uncontrolled intraocular pressure due to hyphema. While most eyes recovered to 20/20 or 20/25 vision, they remain at risk for lifelong ocular complications due to the increased risk of traumatic glaucoma.

Editorial: Disentangling the Impact of Reticular Pseudodrusen Phenotype and the ARMS2/HTRA1 Risk Allele in Geographic Atrophy: The AREDS 2 Study Report 32

/在：

 

Editorial: Disentangling the Impact of Reticular Pseudodrusen Phenotype and the ARMS2/HTRA1 Risk Allele in Geographic Atrophy: The AREDS 2 Study Report 32

Created
Tags Retina
Journal Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

中文摘要

本文探討了在AREDS 2研究中reticular pseudodrusen (RPD)與ARMS2 / HTRA1 risk allele對geographic atrophy(GA)的影響，並證實了具有RPD和ARMS2風險等位基因的眼睛的GA生長速度比沒有它們的眼睛更快。通過中介分析，本研究顯示RPD的存在不會介導ARMS2基因型和GA生長之間的聯繫。此研究對於揭示GA進展的遺傳和臨床風險因素的作用有重要意義，並提示在GA的治療試驗中，需要考慮ARMS2和RPD狀態以提高其精度和功效。然而，該研究也存在一些限制，例如使用FAF而不是更敏感的技術來確定RPD狀態。總體而言，該研究是針對解開RPD狀態和ARMS2基因型對GA進展影響的一個重要進展，並對臨床實踐和臨床試驗產生了重要影響。

English Abstract

The article discusses the results of a post hoc analysis of 771 eyes with geographic atrophy (GA) from the Age-Related Eye Disease Study 2, which aimed to determine the impact of reticular pseudodrusen (RPD) phenotype and ARMS2 or HTRA1 risk allele presence, or both, on GA progression. The analysis confirmed that GA growth was significantly faster in eyes with RPD and in individuals carrying the ARMS2 risk alleles, and that RPD presence was associated with faster progression to the central macula in noncentral GA. However, the authors found that RPD does not mediate the association between ARMS2 genotype and GA growth, suggesting that these two risk factors influence GA via potentially independent mechanisms. The study has important implications for clinical trials of GA, and the authors suggest that ARMS2 and RPD status should be considered during patient selection and randomization to increase the precision and power of these trials. The study is also an important step toward dissecting the roles of genetic and clinical risk factors in GA progression, and the findings suggest that RPD phenotype and ARMS2 or HTRA1 genotype are likely contributing via distinct mechanisms.

Augmented-Dose Unilateral Recession-Resection Procedure in Acute Acquired Comitant Esotropia

/在：

Augmented-Dose Unilateral Recession-Resection Procedure in Acute Acquired Comitant Esotropia

 

Created
Tags NeuroPediatric
Journal Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

Ophthalmology Volume 130, Number 5, May 2023

中文摘要

研究的目的是比較 acute acquired comitant esotropia (AACE) 患者單側medial rectus recession and lateral rectus resection手術量與常見內斜視形式的手術量的差異，以提供 AACE 手術計劃的劑量反應參考。本研究分析了只有達到運動和感覺成功的患者，最少要有 3 個月的隨訪時間。通過多變量回歸模型分析了 AACE 中的手術劑量反應。为了消除可比性偏差，手术量在AACE患者中要更大一些， 在矯正小斜角度的患者中，调整后的组差异为0.49 mm（95%置信区间[CI]，0.34-0.65 mm; P <0.001）in MR recession，在 LR 切除中为1.68 mm（95% CI，1.25-2.11 mm; P <0.001），在偏差小於40 prism diopters的患者中，以及与 LR 切除的组差异为1.22 mm（95% CI，0.76-1.68 mm; P <0.001），在偏差超过40 prism diopters 的患者中，与 LR 切除的组差异为1.22 mm（95% CI，0.76-1.68 mm; P <0.001）。在考虑拦截的调整模型中，对于具有小于 30 prism diopters 的偏差的患者，在 MR recession和 LR resection的剂量反应中，预计每额外增加 1 毫米 MR recession将有 5.11 prism diopters（95% CI，0.98-9.23 prism diopter ; P = 0.02） 的偏差被矫正，每额外增加 1 毫米 LR resection反应的偏差量为 2.51 prism diopters（95% CI，0.57-4.45 prism diopter/mm; P = 0.02）。在偏差超过 30 prism diopters 的患者中，除 30 prism diopters 外剩余偏差的纠正，需要额外 LR resction 5.48 prism diopters/mm（95% CI，4.56-6.40 prism diopter/mm; P <0.001）。這些研究結果提供了定量證據，表明對於 AACE 患者應進行增量 RR 手術以獲得良好的手術結果。

English Abstract

The study aimed to compare the surgical amount of unilateral medial rectus recession and lateral rectus resection (RR) in patients with acute acquired comitant esotropia (AACE) versus common forms of esotropia and to provide dose-response reference for surgical planning in AACE. The study included patients who achieved motor and sensory success with a minimum follow-up of 3 months. Multivariable regression models were used to analyze the dose-response of MR recession and LR resection in AACE. The findings suggest that augmented-dose unilateral RR should be performed in AACE for favorable surgical outcomes. The study also proposed a surgical dose calculation method based on respective dose responses of MR recession and LR resection and different-sized deviations (< 30 prism diopters and > 30 prism diopters) to provide a reference for unilateral RR planning in AACE.

The Efficacy of Defocus Incorporated Multiple Segments Lenses in Slowing Myopia Progression

/在：

The Efficacy of Defocus Incorporated Multiple Segments Lenses in Slowing Myopia Progression

 

Created
Tags CGMHOPHPediatricRefraction
Journal Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

Ophthalmology Volume 130, Number 5, May 2023

中文摘要

本研究旨在探討defocus incorporated multiple segments (DIMS)眼鏡鏡片在減緩近視進展方面的功效。研究結果顯示，相較於single-vision (SV)眼鏡鏡片，DIMS鏡片能夠顯著地減緩近視進展，其中在2年觀察期內，DIMS相對於SV的進展率減緩達59%。該研究的樣本來自於中國艾爾眼科醫院集團的9家附屬醫院的臨床病歷。經過相應的配對，研究結果顯示，年齡、性別和baseline近視度數等相關因素對減緩近視進展的功效沒有顯著影響。然而，該研究還發現，患有較輕近視的患者從DIMS鏡片中獲益更多。綜合而言，這項研究證實了DIMS鏡片減緩近視進展的功效，但也存在著一些局限性，例如樣本來自單一地區的醫院和病歷回顧性質等。

English Abstract

The article discusses a study on the efficacy of defocus incorporated multiple segments (DIMS) spectacle lenses in slowing the progression of myopia. Myopia is becoming a global public health concern due to its increasing prevalence, particularly in East and Southeast Asia. The DIMS spectacle lens was designed to slow myopia progression by exerting myopic defocus in the peripheral retina and was reported to slow myopia progression significantly in a randomized controlled trial. The study collected patient records involving the use of DIMS and single-vision (SV) spectacle lenses between July 1, 2018, and November 30, 2020, from 9 subsidiary hospitals of Aier Eye Hospital Group in China. The data were analyzed, and the study confirmed the myopia control effect of DIMS over SV spectacle lenses. The study also found that patients with lower myopia would benefit more from DIMS lenses, but the progression in patients with high myopia was only minimally affected by using DIMS spectacles. Compliance was another important factor, as more wearing time was found to be associated with greater treatment efficacy. However, the study had several limitations due to its retrospective nature, and a prospective longitudinal study is being conducted to explore if treatment efficacy can be increased by regular reminders